Y-Biologics Inc

XKRX:338840 (Korea (the Republic of))  
â‚© 8800.00 (+0.69%) May 31
At Loss
P/B:
5.77
Market Cap:
â‚© 129.91B ($ 93.93M)
Enterprise V:
â‚© 113.42B ($ 82.01M)
Volume:
101.94K
Avg Vol (2M):
290.51K
Volume:
101.94K
At Loss
Avg Vol (2M):
290.51K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Y-Biologics Inc ( ) from 2023 to Jun 01 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Y-Biologics stock (XKRX:338840) PE ratio as of Jun 01 2024 is 0. More Details

Y-Biologics Inc (XKRX:338840) PE Ratio (TTM) Chart

To

Y-Biologics Inc (XKRX:338840) PE Ratio (TTM) Historical Data

Total 120
  • 1
  • 2
Y-Biologics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-01 At Loss 2024-03-26 At Loss
2024-05-31 At Loss 2024-03-25 At Loss
2024-05-30 At Loss 2024-03-22 At Loss
2024-05-29 At Loss 2024-03-21 At Loss
2024-05-28 At Loss 2024-03-20 At Loss
2024-05-27 At Loss 2024-03-19 At Loss
2024-05-24 At Loss 2024-03-18 At Loss
2024-05-23 At Loss 2024-03-15 At Loss
2024-05-22 At Loss 2024-03-14 At Loss
2024-05-21 At Loss 2024-03-13 At Loss
2024-05-20 At Loss 2024-03-12 At Loss
2024-05-17 At Loss 2024-03-11 At Loss
2024-05-16 At Loss 2024-03-08 At Loss
2024-05-14 At Loss 2024-03-07 At Loss
2024-05-13 At Loss 2024-03-06 At Loss
2024-05-10 At Loss 2024-03-05 At Loss
2024-05-09 At Loss 2024-03-04 At Loss
2024-05-08 At Loss 2024-02-29 At Loss
2024-05-07 At Loss 2024-02-28 At Loss
2024-05-03 At Loss 2024-02-27 At Loss
2024-05-02 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-08 At Loss
2024-04-16 At Loss 2024-02-07 At Loss
2024-04-15 At Loss 2024-02-06 At Loss
2024-04-12 At Loss 2024-02-05 At Loss
2024-04-11 At Loss 2024-02-02 At Loss
2024-04-09 At Loss 2024-02-01 At Loss
2024-04-08 At Loss 2024-01-31 At Loss
2024-04-05 At Loss 2024-01-30 At Loss
2024-04-04 At Loss 2024-01-29 At Loss
2024-04-03 At Loss 2024-01-26 At Loss
2024-04-02 At Loss 2024-01-25 At Loss
2024-04-01 At Loss 2024-01-24 At Loss
2024-03-29 At Loss 2024-01-23 At Loss
2024-03-28 At Loss 2024-01-22 At Loss
2024-03-27 At Loss 2024-01-19 At Loss

Y-Biologics Inc (XKRX:338840) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Compare
Compare
Traded in other countries / regions
338840.Korea
IPO Date
2023-12-05
Description
Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.